ERCC1 not effective for guiding therapeutic decisions

ERCC1 not effective for guiding therapeutic decisions
Currently available antibodies for the excision repair cross-complementation group 1 protein are not adequate for therapeutic decision-making regarding the potential efficacy of cisplatin-containing treatment in patients with non-small-cell lung cancer, according to a study published in the March 21 issue of the New England Journal of Medicine.

(HealthDay)—Currently available antibodies for the excision repair cross-complementation group 1 (ERCC1) protein are not adequate for therapeutic decision-making regarding the potential efficacy of cisplatin-containing treatment in patients with non-small-cell lung cancer, according to a study published the March 21 issue of the New England Journal of Medicine.

Luc Friboulet, Ph.D., from University of Paris, used the 8F1 antibody to measure the level of expression of ERCC1 protein using immunohistochemical analysis in a validation set of 499 patient samples obtained from two independent phase 3 trials.

The researchers were unable to validate the predictive effect of immunostaining for ERCC1 protein. They found discordance in staining for ERCC1 suggestive of a change in the performance of the 8F1 antibody since 2006, when an initial correlation between the absence of ERCC1 expression and platinum response was identified. None of the 16 antibodies could distinguish among the four ERCC1 protein isoforms. A protein capable of nucleotide excision repair and resistance was only produced by one isoform.

"Immunohistochemical analysis with the use of currently available ERCC1 did not specifically detect the unique functional ERCC1 isoform," the authors write.

Eli Lilly funded the study.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

New genetic techniques to combat lung cancer

Apr 25, 2008

New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) ...

Novel structure proteins could play a role in apoptosis

Jul 24, 2008

Isoforms from Novel Structure Proteins (NSP), a new family of genes discovered by researchers in the Sbarro Institute for Cancer Research and Molecular Medicine in Temple University's College of Science and Technology, could ...

Recommended for you

Blood biomarker may detect lung cancer

3 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

19 hours ago

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments